Abstract
Carumonam (CRMN, AMA-1080), a novel synthetic monocyclic β-lactam antibiotic, was basically and clinically evaluated with the following results: 1) Antimicrobial activity: CRMN was specifically active against aerobic Gram-negative bacteria including Pseudomonas aeruginosa. Its activity against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Enterobacter cloacae, Enterobacter aerogenes and P. aeruginosa was in general equal or superior to that of the third-generation cephems such as ceftizoxime, cefoperazone and latamoxef. 2) Carumonam level in serum and sputum: CRMN was drip infused for 1 h to five patients with chronic respiratory infections at a dose of 1 or 2 and its serum and sputum levels were assayed microbiologically. Peak serum levels were 33.5—64.7 μg/ml with the 1 g dose and 88.4—146.6μg/ml with the 2 g dose at the end of drip infusion. Peak sputum levels were 1.21—6.56 μg/ml (2 g) at 2 to 4 h after infusion. The average ratio of peak levels in sputum to those in serum was 3.7 and 5.6%, respectively. 3) Clinical results: CRMN was administered to 13 patients with various respiratory infections. Clinical response was excellent in 2, good in 6, fair in 3 and poor in 1 patient, and 1 patient was not evaluable. The overall efficacy rate was 66.7%. In one patient S-GPT and urobilinogen values were transiently elevated mildly to moderately. We therefore conclude that CRMN is a useful antibiotics in treating patients with respiratory infections due to aerobic Gram-negative bacteria.
| Original language | English |
|---|---|
| Pages (from-to) | 450-469 |
| Number of pages | 20 |
| Journal | Chemotherapy |
| Volume | 35 |
| DOIs | |
| Publication status | Published - 1987 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Drug Discovery
- Pharmacology (medical)
- Infectious Diseases
Cite this
Laboratory Studies And Clinical Evaluation Of Carumonam In Respiratory Infections. / Sasayama, Kazuo; Yamashita, Kyoko; Dotsu, Yasumasa; Miyazaki, Takashige; Nakazato, Hiroko; Shigeno, Hideaki; Koga, Hironobu; Suyama, Takashi; Nagasawa, Masao; Mori, Kenji; Fukuda, Yoshiaki; Hayashi, Toshiaki; Ito, Naomi; Shigeno, Yoshiteru; Yamaguchi, Keizo; Hirota, Masaki; Saito, Atsushi; Hara, Kohei; Sugawara, Kazuyuki; Shimoguchi, Kazunori; Tomono, Kazunori; Kusano, Nobuchika; Masuyama, Yasuharu; Oe, Toshiyuki; Ishizaki, Takeshi.
In: Chemotherapy, Vol. 35, 1987, p. 450-469.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Laboratory Studies And Clinical Evaluation Of Carumonam In Respiratory Infections
AU - Sasayama, Kazuo
AU - Yamashita, Kyoko
AU - Dotsu, Yasumasa
AU - Miyazaki, Takashige
AU - Nakazato, Hiroko
AU - Shigeno, Hideaki
AU - Koga, Hironobu
AU - Suyama, Takashi
AU - Nagasawa, Masao
AU - Mori, Kenji
AU - Fukuda, Yoshiaki
AU - Hayashi, Toshiaki
AU - Ito, Naomi
AU - Shigeno, Yoshiteru
AU - Yamaguchi, Keizo
AU - Hirota, Masaki
AU - Saito, Atsushi
AU - Hara, Kohei
AU - Sugawara, Kazuyuki
AU - Shimoguchi, Kazunori
AU - Tomono, Kazunori
AU - Kusano, Nobuchika
AU - Masuyama, Yasuharu
AU - Oe, Toshiyuki
AU - Ishizaki, Takeshi
PY - 1987
Y1 - 1987
N2 - Carumonam (CRMN, AMA-1080), a novel synthetic monocyclic β-lactam antibiotic, was basically and clinically evaluated with the following results: 1) Antimicrobial activity: CRMN was specifically active against aerobic Gram-negative bacteria including Pseudomonas aeruginosa. Its activity against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Enterobacter cloacae, Enterobacter aerogenes and P. aeruginosa was in general equal or superior to that of the third-generation cephems such as ceftizoxime, cefoperazone and latamoxef. 2) Carumonam level in serum and sputum: CRMN was drip infused for 1 h to five patients with chronic respiratory infections at a dose of 1 or 2 and its serum and sputum levels were assayed microbiologically. Peak serum levels were 33.5—64.7 μg/ml with the 1 g dose and 88.4—146.6μg/ml with the 2 g dose at the end of drip infusion. Peak sputum levels were 1.21—6.56 μg/ml (2 g) at 2 to 4 h after infusion. The average ratio of peak levels in sputum to those in serum was 3.7 and 5.6%, respectively. 3) Clinical results: CRMN was administered to 13 patients with various respiratory infections. Clinical response was excellent in 2, good in 6, fair in 3 and poor in 1 patient, and 1 patient was not evaluable. The overall efficacy rate was 66.7%. In one patient S-GPT and urobilinogen values were transiently elevated mildly to moderately. We therefore conclude that CRMN is a useful antibiotics in treating patients with respiratory infections due to aerobic Gram-negative bacteria.
AB - Carumonam (CRMN, AMA-1080), a novel synthetic monocyclic β-lactam antibiotic, was basically and clinically evaluated with the following results: 1) Antimicrobial activity: CRMN was specifically active against aerobic Gram-negative bacteria including Pseudomonas aeruginosa. Its activity against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Enterobacter cloacae, Enterobacter aerogenes and P. aeruginosa was in general equal or superior to that of the third-generation cephems such as ceftizoxime, cefoperazone and latamoxef. 2) Carumonam level in serum and sputum: CRMN was drip infused for 1 h to five patients with chronic respiratory infections at a dose of 1 or 2 and its serum and sputum levels were assayed microbiologically. Peak serum levels were 33.5—64.7 μg/ml with the 1 g dose and 88.4—146.6μg/ml with the 2 g dose at the end of drip infusion. Peak sputum levels were 1.21—6.56 μg/ml (2 g) at 2 to 4 h after infusion. The average ratio of peak levels in sputum to those in serum was 3.7 and 5.6%, respectively. 3) Clinical results: CRMN was administered to 13 patients with various respiratory infections. Clinical response was excellent in 2, good in 6, fair in 3 and poor in 1 patient, and 1 patient was not evaluable. The overall efficacy rate was 66.7%. In one patient S-GPT and urobilinogen values were transiently elevated mildly to moderately. We therefore conclude that CRMN is a useful antibiotics in treating patients with respiratory infections due to aerobic Gram-negative bacteria.
UR - http://www.scopus.com/inward/record.url?scp=85007860961&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85007860961&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1953.35.Supplement2_450
DO - 10.11250/chemotherapy1953.35.Supplement2_450
M3 - Article
AN - SCOPUS:85007860961
VL - 35
SP - 450
EP - 469
JO - Chemotherapy
JF - Chemotherapy
SN - 0009-3165
ER -